<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:8.0pt;
	margin-left:0cm;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
h1
	{mso-style-link:"Heading 1 Char";
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:0cm;
	line-height:107%;
	page-break-after:avoid;
	font-size:16.0pt;
	font-family:"Calibri Light",sans-serif;
	color:#2F5496;
	font-weight:normal;}
h2
	{mso-style-link:"Heading 2 Char";
	margin-top:2.0pt;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:0cm;
	line-height:107%;
	page-break-after:avoid;
	font-size:13.0pt;
	font-family:"Calibri Light",sans-serif;
	color:#2F5496;
	font-weight:normal;}
h3
	{mso-style-link:"Heading 3 Char";
	margin-top:2.0pt;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:0cm;
	line-height:107%;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Calibri Light",sans-serif;
	color:#1F3763;
	font-weight:normal;}
a:link, span.MsoHyperlink
	{color:#0563C1;
	text-decoration:underline;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:8.0pt;
	margin-left:36.0pt;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:8.0pt;
	margin-left:36.0pt;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	font-family:"Calibri Light",sans-serif;
	color:#2F5496;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-link:"Heading 2";
	font-family:"Calibri Light",sans-serif;
	color:#2F5496;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-family:"Calibri Light",sans-serif;
	color:#1F3763;}
.MsoChpDefault
	{font-family:"Calibri",sans-serif;}
.MsoPapDefault
	{margin-bottom:8.0pt;
	line-height:107%;}
@page WordSection1
	{size:595.3pt 841.9pt;
	margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0cm;}
ul
	{margin-bottom:0cm;}
-->
</style>

</head>

<body lang=EN-AU link="#0563C1" vlink="#954F72" style='word-wrap:break-word'>

<div class=WordSection1>

<h1>2020A06Describe how the effects of warfarin can be reversed when URGENT
surgery is indicated (40%).<br>
For each option discuss the advantages and disadvantages (60%).</h1>

<p class=MsoNormal><span lang=EN-US>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-US>&nbsp;</span></p>

<h3><span lang=EN-US>Intro:</span></h3>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=122 valign=top style='width:91.85pt;border:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><span
  lang=EN-US>Mechanism</span></p>
  </td>
  <td width=479 valign=top style='width:358.95pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraph style='margin-top:0cm;margin-right:0cm;margin-bottom:
  0cm;margin-left:30.15pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>Vitamin K epoxide reductase inhibitor</span></p>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><span
  lang=EN-US><img width=297 height=223 id="Picture 5"
  src="2020A06_warfarin_reversal_files/image001.jpg"></span></p>
  </td>
 </tr>
 <tr>
  <td width=122 valign=top style='width:91.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><span
  lang=EN-US>Factors affected</span></p>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><span
  lang=EN-US>(half life)</span></p>
  </td>
  <td width=479 valign=top style='width:358.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.15pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>Procoagulants: II (60h), VII (6h), IX (24h), X
  (36h)</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.15pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>Anticoagulants: protein C (8h), protein S
  (30h)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-US>&nbsp;</span></p>

<h2><span lang=EN-US>Reversal considerations:</span></h2>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=122 valign=top style='width:91.85pt;border:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><span
  lang=EN-US>Determinants</span></p>
  </td>
  <td width=479 valign=top style='width:358.95pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.15pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>Urgency of surgery</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.15pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>Active bleeding</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.15pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>Degree of reversal required (e.g. neuraxial vs
  superficial)</span></p>
  </td>
 </tr>
 <tr>
  <td width=122 valign=top style='width:91.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><span
  lang=EN-US>Monitoring</span></p>
  </td>
  <td width=479 valign=top style='width:358.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.15pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>INR is sensitive to factor VII (short t<sub>1/2</sub>)
  &gt;&gt; factor II (long t<sub>1/2</sub>)</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.15pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>Hence INR will normalise before coagulation is
  restored</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.15pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>Hence need INR </span><span lang=EN-US>&#8804;</span><span
  lang=EN-US>1.2 for safe neuraxial block after stopping warfarin<br>
  (source: ASRA guidelines)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-US>&nbsp;</span></p>

<h3><span lang=EN-US>Reversal options:</span></h3>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=122 valign=top style='width:91.85pt;border:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><span
  lang=EN-US>1.Expectant</span></p>
  </td>
  <td width=479 valign=top style='width:358.95pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.25pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>i.e. drug washout -&gt; regenerate Vit K -&gt;
  regenerate clotting factors</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.25pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>t<sub>1/2&#946;</sub> 40 hours -&gt; offset in
  5 days</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.25pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>&#8593;Duration if: Vit K deficient e.g.
  malnourished, CYP inhibitor (e.g. cimetidine), CYP competition e.g.
  amiodarone</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.25pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>&#8595;Duration if: CYP inducer (e.g. barbiturates)</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.25pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>Can operate immediately if a) low risk of
  bleeding b) benign consequences of bleeding c) easily compressible site</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.25pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>Pro: &#8595;risk thrombotic events, less
  disruptive to patient</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.25pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>Con: slow offset, &#8593;risk surgical
  bleeding</span></p>
  </td>
 </tr>
 <tr>
  <td width=122 valign=top style='width:91.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><span
  lang=EN-US>2.Vitamin K</span></p>
  </td>
  <td width=479 valign=top style='width:358.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.25pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>i.e. replenish substrate -&gt; regenerate
  clotting factors</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.25pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>PO 1-2mg for effect in 12-24 hours</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.25pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>IV 5-10mg for effect in 6-12 hours</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.25pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>Pro: fairly rapid reversal, obviates risks of
  blood products</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.25pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>Con: insufficient if very high INR or if
  active bleeding, difficult to restart warfarin after a big dose of Vitamin K</span></p>
  </td>
 </tr>
 <tr>
  <td width=122 valign=top style='width:91.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><span
  lang=EN-US>2.FFP</span></p>
  </td>
  <td width=479 valign=top style='width:358.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.15pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>Contains all clotting factors</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.15pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>IV 15-30mL/kg (or 2-4mL/kg if with
  prothrombinex)</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.15pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>Also give Vit K to avoid rebound
  anticoagulation</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.15pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>Pro: immediate</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.15pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>Con: 15-30mL/kg = risk of TACO, risks of
  allogeneic transfusion</span></p>
  </td>
 </tr>
 <tr>
  <td width=122 valign=top style='width:91.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><span
  lang=EN-US>3.Prothrombinex</span></p>
  </td>
  <td width=479 valign=top style='width:358.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.15pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>Contains factors 2, 9, 10</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.15pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>IV 25-50 units/kg</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.15pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>Also give Vit K to avoid re-bound
  anticoagulation</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.15pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>Pro: immediate, universally compatible</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.15pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>Con: factor 7 absent in Australian PCC</span></p>
  </td>
 </tr>
 <tr>
  <td width=122 valign=top style='width:91.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><span
  lang=EN-US>4.FEIBA</span></p>
  </td>
  <td width=479 valign=top style='width:358.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.15pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>Contains active factor 7a, inactive factors
  2,9,10</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.15pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>IV 50-100 units/kg</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.15pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>Also give Vit K to avoid rebound
  anticoagulation</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.15pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>Pro: contains all deficient coag factors</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.15pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>Con: less data for warfarin reversal</span></p>
  </td>
 </tr>
 <tr>
  <td width=122 valign=top style='width:91.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><span
  lang=EN-US>5.Novoseven</span></p>
  </td>
  <td width=479 valign=top style='width:358.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.15pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>Activated Factor 7a</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.15pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>IV 50mcg/kg</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.15pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>Given in addition to FFP and/or prothrombinex</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.15pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>Only if persistent uncontrollable haemorrhage
  despite all other physiological, pharmacological and surgical efforts</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.15pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>Pro: immediate</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.15pt;text-indent:-21.25pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-US>Con: very expensive, short half life, high
  risk of thrombotic complications</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-US>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-US>Feedback welcome at </span><a
href="mailto:ketaminenightmares@gmail.com"><span lang=EN-US>ketaminenightmares@gmail.com</span></a></p>

<p class=MsoNormal><span lang=EN-US>&nbsp;</span></p>

</div>

</body>

</html>
